Most Read Articles
3 days ago
Tetanus toxoid 5 Lf, diphtheria toxoid 2 Lf, pertussis toxoid 2.5 mcg, filamentous haemagglutinin 5 mcg, fimbriae types 2 and 3 5 mcg, pertactin 3 mcg
Pearl Toh, 22 Oct 2020
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Jairia Dela Cruz, 3 days ago
The selective serotonin reuptake inhibitor escitalopram holds promise in the prevention of Alzheimer’s disease, reducing amyloid-β-42 levels in cerebrospinal fluid and brain tissue in older adults with normal cognitive function, according to recent evidence.
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.

Meth-associated HF with reduced ejection fraction reversible

13 Nov 2020

Patients with methamphetamine-associated heart failure (HF) with reduced left ventricular (LV) ejection fraction (HFrEF) have a more severe disease compared with other HF patients, a study has found. But more importantly, quitting meth leads to an improvement in LV function with fewer hospital admissions, suggesting that meth-associated HFrEF may be reversed.

The retrospective analysis involved 51 HFrEF patients (28 methamphetamine users and 23 controls) and 60 HF patients with preserved EF (HFpEF; 28 methamphetamine users and 32 controls). Among meth users, 14 of those with reduced EF and 13 of those with preserved EF had quit the drug at the 1-year follow-up.

In the meth-HFrEF group (mean age, 51 years; 82.1 percent male), cessation of drug use resulted in an improvement in EF (10.6 percent; p=0.009) and fewer HF admissions per year compared with continued use (median, 0.0 vs 2.0; p=0.039).

On the other hand, meth-HFpEF patients (mean age, 50 years; 60.7 percent male) vs controls had higher baseline right ventricular systolic pressure (median, 53.44 vs 36.64; p=0.011) and lower lateral E/E’ ratio (8.1 vs 11.2; p<0.01). There were no significant improvements in echocardiographic parameters and clinical outcomes seen following discontinuation of drug use in this group.

The findings highlight the importance of initiating efforts focused on methamphetamine cessation to improve outcomes for users with HFrEF. Meanwhile, further investigation is warranted to shed light on occult abnormalities in LV function among meth users with HFpEF.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
3 days ago
Tetanus toxoid 5 Lf, diphtheria toxoid 2 Lf, pertussis toxoid 2.5 mcg, filamentous haemagglutinin 5 mcg, fimbriae types 2 and 3 5 mcg, pertactin 3 mcg
Pearl Toh, 22 Oct 2020
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Jairia Dela Cruz, 3 days ago
The selective serotonin reuptake inhibitor escitalopram holds promise in the prevention of Alzheimer’s disease, reducing amyloid-β-42 levels in cerebrospinal fluid and brain tissue in older adults with normal cognitive function, according to recent evidence.
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.